Cutaneous manifestations associated with SARS-CoV-2 : an emerging topic in a pandemic era
© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
A 70-year-old man was admitted to our COVID-19 ward with thoracalgia, productive mucus cough, fatigue and erythematous-violaceous macules on the inner side of feet and interdigital regions. The patient was started on oxygen and dexamethasone. On the day of discharge, he maintained the skin changes despite the resolution of COVID-19 symptoms. A 57-year-old woman initially presented with diffuse urticarial rash on the cervical and chest region. Oral cetirizine was started, and pruritus improved. Thirty days after the discharge, the patient maintained the rash, but without pruritus. A 49-year-old man was admitted with thoracalgia, shortness of breath, dry cough and urticarial rash on the cervical and chest region. The patient was treated with cetirizine. The pruritus improved, and 5 days after discharge, the urticarial areas completely disappeared.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
BMJ case reports - 14(2021), 9 vom: 03. Sept. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Luís, Helena [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 07.09.2021 Date Revised 31.05.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/bcr-2021-244763 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330223437 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM330223437 | ||
003 | DE-627 | ||
005 | 20231225210825.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/bcr-2021-244763 |2 doi | |
028 | 5 | 2 | |a pubmed24n1100.xml |
035 | |a (DE-627)NLM330223437 | ||
035 | |a (NLM)34479898 | ||
035 | |a (PII)e244763 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Luís, Helena |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cutaneous manifestations associated with SARS-CoV-2 |b an emerging topic in a pandemic era |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.09.2021 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a A 70-year-old man was admitted to our COVID-19 ward with thoracalgia, productive mucus cough, fatigue and erythematous-violaceous macules on the inner side of feet and interdigital regions. The patient was started on oxygen and dexamethasone. On the day of discharge, he maintained the skin changes despite the resolution of COVID-19 symptoms. A 57-year-old woman initially presented with diffuse urticarial rash on the cervical and chest region. Oral cetirizine was started, and pruritus improved. Thirty days after the discharge, the patient maintained the rash, but without pruritus. A 49-year-old man was admitted with thoracalgia, shortness of breath, dry cough and urticarial rash on the cervical and chest region. The patient was treated with cetirizine. The pruritus improved, and 5 days after discharge, the urticarial areas completely disappeared | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a dermatology | |
700 | 1 | |a Barros, Carolina |e verfasserin |4 aut | |
700 | 1 | |a André, Diogo |e verfasserin |4 aut | |
700 | 1 | |a Malheiro, Alexandra |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMJ case reports |d 2008 |g 14(2021), 9 vom: 03. Sept. |w (DE-627)NLM209291001 |x 1757-790X |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2021 |g number:9 |g day:03 |g month:09 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/bcr-2021-244763 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2021 |e 9 |b 03 |c 09 |